Clinical trials located in

Salerno

Salerno city is located in Italy. Currently, 12 clinical trials are being conducted in this city.

Salerno, a city in Italy’s Campania region, boasts a rich history dating back to ancient times. It is renowned for its stunning Amalfi Coast proximity and the Salerno Cathedral, which houses the relics of St. Matthew. The city played a pivotal role during World War II as the site of the Allied invasion. Salerno is also celebrated for its medical school, Schola Medica Salernitana, considered the world’s first medical university, highlighting its long-standing tradition of medical scholarship and education.

  • CT-EU-00036552

    Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Testing zamaglutenase for gluten breakdown in celiac disease treatment

    This study focuses on a medicine called zamaglutenase (TAK-062) that may help people with celiac disease. Celiac disease is a condition where the body can’t process gluten, which is found in wheat, rye, and barley. When people with celiac disease eat gluten, their immune system reacts by damaging the small intestine. TAK-062 is meant to break down the gluten in a person’s stomach, possibly helping the body cope better. The study needs around 357 volunteers, who will be split into two groups at random. Both groups will involve adults over 18 years of age. The first group will get a placebo (a medicine-like substance with no actual medicine) and a gluten bar, and the other group will get a dose of TAK-062 alongside the gluten bar. After some time, a committee will check the results of the first group. Depending on what they find, the study may then include teenagers, and the second group will start. Just like any medicine, TAK-062 may or may not cause side effects. Even seemingly unrelated health problems that happen during the study are important, as they could be linked to the medicine, even if it’s not clear at first. This study aims to find clear and truthful results about how TAK-062 works for people with celiac disease.

    BelgiumFranceItalyPolandSpainUnited Kingdom
  • Testing ravulizumab for transplant-related blood complications

    The study is examining a drug called ravulizumab used in adults and teenagers with a blood vessel disease called thrombotic microangiopathy (TMA) after a bone marrow transplant. Sometimes, new cells growing after a bone marrow transplant can cause problems in the blood vessels leading to TMA. So this study will investigate whether ravulizumab can help in this situation. In the first stage, each participant will receive the drug to determine the best dose. In the second phase, some will receive ravulizumab and best supportive care, while others will receive placebo and best supportive care. After 26 weeks of treatment, doctors will continue to monitor and record the patients’ health for another 26 weeks. Special blood tests will be done to check if the medicine is working.

    BelgiumFranceGermanyGreeceItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing the safety and efficiency of elenestinib in mastocytosis patients

    This study evaluates the drug BLU-263 plus supportive care versus placebo in patients with Indolent Systemic Mastocytosis (ISM), a condition where mast cells accumulate in body tissues. It aims to see if BLU-263 can better control symptoms than standard treatments. The study has several parts, enrolling patients with ISM and some with monoclonal mast cell activation syndrome (mMCAS). The main focus is the drug’s effectiveness and safety in managing ISM symptoms.

    AustriaBelgiumFranceGermanyItalyNetherlandsNorwayPortugalSpainUnited Kingdom
  • New treatment study for multiple system atrophy patients

    This study investigates TAK-341’s effectiveness in treating multiple system atrophy (MSA), a progressive neurological disorder. Around 138 participants will receive either TAK-341 or a placebo through regular intravenous infusions over 52 weeks. The trial primarily measures changes in the Unified Multiple System Atrophy Rating Scale Part I (UMSARS) to assess improvement in symptoms. This research is significant for understanding TAK-341’s potential in managing MSA, providing new insights into treatment options for this challenging condition.

    AustriaDenmarkFranceGermanyItalyPortugalSpainUnited Kingdom
  • Studying tozorakimab for long-term safety in patients with chronic obstructive pulmonary disease

    The research study focuses on Tozorakimab’s long-term safety and efficacy in adults over 40 with frequent COPD flare-ups. It aims to evaluate the time until the first severe flare-up post-treatment, comparing it with the effects of current COPD treatments. The study also assesses Tozorakimab’s additional benefits alongside standard care and monitors participants’ blood for drug levels and physiological reactions. This research is key in developing improved management strategies for COPD.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainSwedenUnited Kingdom
  • Tozorakimab trial for chronic obstructive pulmonary disease (COPD) treatment

    This study is checking the effectiveness and safety of two different dose levels of a medication called tozorakimab for treating adults suffering from a long-term lung disease known as symptomatic chronic obstructive pulmonary disease (COPD). COPD patients participating in this study must have had at least two ‘moderate’ or one ‘severe’ exacerbations (flare-ups) over the last year. The study will compare how well tozorakimab works compared to an inactive substance (placebo) in delaying the time to the first exacerbation and any changes to lung function tests, such as the FEV1 test. The participants’ demonstrations of improvement based on scoring systems related to symptoms severity will also be evaluated.

    FranceGermanyGreeceItalyPolandRomaniaUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain

See more clinical trials in other cities in Italy:

.